Vicki Wheelock
Neurology · Sacramento, CANPI 1871579458
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $16,350 of the $16,544 with a category attached, or 98.8%. Roche Products Limited accounts for 61.5% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2021 at $7,700 and has fallen 80.5% since, to $1,500 in 2024.
Across 16 payments — averaging $1034.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Roche Products Limited$10K
- F. Hoffmann-la Roche AG$6K
- Teva Pharmaceuticals USA, Inc.$177
Across 29 payments — averaging $29,496 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$815K
- F. Hoffmann-la Roche AG$40K
What the payments were for
- Consulting fees$16,35099%
- Food & beverage$170%
- Education$1771%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Roche Products Limited | 10 | $10,167 |
| F. Hoffmann-la Roche AG | 4 | $6,200 |
| Teva Pharmaceuticals USA, Inc. | 2 | $177 |
How this compares
$16,544 in reported general payments places this provider in the 80th percentile of 1,996 neurology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 12 | $91,470 |
| RytaryCarbidopa/Levodopa | 20 | $38,369 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 30 | $3,375 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 13 | $397 |
| Olanzapine | 25 | $283 |
| Donepezil Hcl | 12 | $176 |
| Tizanidine Hcl | 11 | $148 |
| Sertraline Hcl | 11 | $114 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $177 | $91,47012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,996 neurology providers in California.
Other neurology in Sacramento
- Lin ZhangSacramento$328K
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
- David LiebeskindLos Angeles$1.9M
- Jack SchimCarlsbad$1.7M
- Parshaw DorrizMission Viejo$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.